|本期目录/Table of Contents|

[1]中华医学会感染病学分会艾滋病丙型肝炎学组 中国疾病预防与控制中心.中国艾滋病诊疗指南(2018 版)[J].传染病信息,2018,06:481-499504.
 AIDS and Hepatitis C Professional Group,Society of Infectious Diseases,Chinese Medical Association,et al.Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)[J].Infectious Disease Information,2018,06:481-499504.
点击复制

中国艾滋病诊疗指南(2018 版)(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年06期
页码:
481-499504
栏目:
特别报道
出版日期:
2018-12-30

文章信息/Info

Title:
Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)
作者:
中华医学会感染病学分会艾滋病丙型肝炎学组 中国疾病预防与控制中心 
Author(s):
AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association; Chinese Center for Disease Control and Prevention
acquired immunodeficiency syndrome; HIV; disgnosis; treatment; guideline
关键词:
获得性免疫缺陷综合征HIV诊断治疗指南
Keywords:
-
分类号:
 R512.91
DOI:
10.3969/j.issn.1007-8134.2018.06.001
文献标识码:
A
摘要:
-
Abstract:
-

参考文献/References


[1] 中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南第三 版(2015 版)[J]. 中华临床感染病杂志,2015,8(5):385- 401. DOI: 10.3760/cma.j.issn.1674-2397.2015.05.001.
[2] World Health Organization. WHO HIV update: global epidemic and progress in scale up and policy uptake[EB/OL].
[2018-09-30]. http://www.who.int/hiv/data/en/.
[3] World Health Organization. Global scientific leaders explore strategies to achieve the 90-90-90 target[R/OL].(2015-07-22)
[2018-09-29]. 22 JULY2015.http://www.unaids.org/en/resources/ presscentre/featurestories/2015/july/20150722_90-90-90-target.
[4] 吴尊友. 我国艾滋病经性传播新特征与防治面临的挑战[J]. 中华流行病学杂志,2018,39(6):707-709. DOI: 10.3760/cma. j.issn.0254-6450.2018.06.002.
[5] 全国艾滋病检测技术规范(2015 年修订版)[J]. 中国病毒 病杂志,2016,6(6):401-427.
[6] 荆凡辉,吕玮,李太生. HIV感染者免疫功能重建新视角:CD4/ CD8 比值[J]. 中国艾滋病性病,2018,24(6):643-646.
[7] Li Y, Han Y, Xie J, et al. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission[J]. AIDS, 2014, 28(4):521-530. DOI: 10.1097/QAD.0000000000000125.
[8] Su B, Moog C. Which antibody functions are important for an HIV vaccine?[J]. Front Immunol, 2014, 5:289. DOI: 10.3389/ fimmu.2014.00289.
[9] Panel on Opportunistic infections in HIV-infected adults and adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America.[S/OL].
[2018-10-02]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adult_oi.pdf.
[10] 卢洪洲. 艾滋病及其相关疾病临床路径. 2 版. 上海:上海科 学技术出版社,2015.
[11] Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients[J]. AIDS, 1998,   12(8):885-893.
[12] Hidalgo A, Falcó V, Mauleón S, et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non-Pneumocystis carinii pneumonia in AIDS patients[J]. Eur Radiol, 2003, 13(5):1179-1184. DOI: 10.1007/s00330-002- 1641-6.
[13] Roger PM, Vandenbos F, Pugliese P, et al. Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus[J]. Clin Infect Dis, 1998, 26(2):509-510.
[14] Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group[J]. Ann Intern Med, 1996, 124(9):792-802.
[15] 中华医学会感染病学分会艾滋病学组,中华医学会热带病 与寄生虫学分会艾滋病学组. HIV 合并结核分枝杆菌感染诊 治专家共识[J]. 中华临床感染病杂志,2017,10(2):81-90. DOI: 10.3760/cma.j.issn.1674-2397.2017.02.001.
[16] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services[S/OL].
[2018-10-02]. http://www.aidsinfo. nih.gov/ ContentFiles/AdultandAdolescentGL.pdf.
[17] European AIDS Clinical Society. EACS Guidelines(Version 9.0) [S/OL]. 2017
[2018-10-02].http://www.eacsociety.org/files/ guidelines_9.0-english.pdf.
[18] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - 2nd ed[S/ OL]. 2016
[2018-10-02]. http://apps.who.int/iris/bitstream/hand le/10665/208825/9789241549684_eng.pdf;jsessionid=B2870D228 8B92D29DBD1158E8D25E207?sequence=1.
[19] Chen J, Zhang R, Wang J, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: a systematic review and meta-analysis[J]. PLoS One, 2011, 6(11):e26827. DOI: 10.1371/journal.pone.0026827.
[20] Chen J, Sun J, Zhang R, et al. T-SPOT.TB in the diagnosis of active tuberculosis among HIV-infected patients with advanced immunodeficiency[J]. AIDS Res Hum Retroviruses, 2011, 27(3):289-294. DOI: 10.1089/aid.2010.0062.
[21] Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4):e1-50. DOI: 10.1093/cid/civ933.
[22] 刘正印,王贵强,朱利平,等. 隐球菌性脑膜炎诊治专家共 识[J]. 中华内科杂志,2018,57(5):317-323. DOI: 10.3760/ cma.j.issn.0578-1426.2018.05.003.
[23] World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children[S/OL].
[2018-10-02]. http://apps. who. int / iris / bitstream / handle / 10665 / 260399 /9789241550277- eng.pdf;jsessionid=222011AFAADA560E12029F954CA43BCD?s equence=1.
[24] Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis[J]. N Engl J Med, 2014, 370(26):2487-2498. DOI: 10.1056/NEJMoa1312884.
[25] 中国疾病预防控制中心性病艾滋病预防控制中心. 国家免 费艾滋病抗病毒药物治疗手册[M]. 3 版. 北京:人民卫 生出版社,2016.
[26] Guidelines for Managing Advanced HIV disease and rapid initiation of antiretroviral therapy[M]. Geneva: World Health Organization, 2017.
[27] 李航,张福杰,卢洪洲,等. HIV 感染合并慢性肾脏病患者 管理专家共识[J]. 中国艾滋病性病,2017,23(6):578-581..
[28] 张仁芳,沈杨,卢洪洲,等. AIDS 相关性淋巴瘤诊治专家共 识[J]. 中国艾滋病性病,2017,23(8):678-682.
[29] 国家卫生和计划生育委员会办公厅. 国家卫生计生委办公厅 关于全面开展预防艾滋病、梅毒和乙肝母婴传播工作的通知 [S]. 2015-04-09.
[30] Panel on Treatment of HIV-Infected Pregnant Women and  Prevention of Perinatal Transmission. Recommendations for  use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United State[S/OL]. (2018.5.30)
[2018-09-28]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
[31] World Health Organization. Updated recommendations on firstline and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance[S/OL].
[2018-10-02]. http://apps.who. int/iris/ bitstream/handle/10665/273632/WHO-CDS-HIV-18.18-eng. pdf?ua=1.
[32] U.S. Public Health Service Working Group. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for post exposure prophylaxis[S/OL].(2018-05-23)
[2018-09-23]. https://www. cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm.
[33] 国家卫生和计划生育委员会办公厅. 国家卫生计生委办公 厅关于印发职业暴露感染艾滋病病毒处理程序规定的通知 [S].2015-07-08.
[34] 国家卫生和计划生育委员会,人力资源社会保障部,安全监 管总局,等. 国家卫生计生委等4 部门关于印发《职业病分 类和目录》的通知[S].2013-12-23.
[35] Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration[J]. Lancet, 2014,384(9939):241-248. DOI: 10.1016/S0140-6736(14)60604-8.
[36] Lebrun D, Hentzien M, Cuzin L, et al. Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort[J]. AIDS, 2017,31(15):2159-2166. DOI: 10.1097/ QAD.0000000000001603.
[37] Worm SW, De Wit S, Weber R, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of Anti-HIV drugs (D:A:D Study)[J]. Circulation, 2009, 119(6):805-811. DOI: 10.1161/CIRCULATIONAHA.108.790857.
[38] Bower M, Palfreeman A, Alfa-Wali M, et al. British HIV Association guidelines for HIV-associated malignancies 2014[J]. HIV Med, 2014,15 Suppl 2:1-92. DOI: 10.1111/hiv.12136.
[39] Meng X, Yin K, Wang J, et al. Effect of CYP2B6 Gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection[J]. PLoS One, 2015,10(6):e0130583. DOI: 10.1371/journal.pone.0130583.
[40] Guo F, Cheng X, Hsieh E, et al. Prospective plasma efavirenz concentration assessment in Chinese HIV - infected adults enrolled in a large multicentre study[J]. HIV Med, 2018
[2018-10-06]. https://onlinelibrary. wiley. com / doi / abs / 10.1111 /hiv. 12607. [published online ahead of print May 15, 2018]. DOI: 10.1111/ hiv.12607.
[41] Carey D, Puls R, Amin J, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study [J]. Lancet Infect Dis, 2015, 15(7):793-802. DOI: 10.1016/ S1473-3099(15)70060-5.
[42] Guaraldi G, Palella FJ. Clinical implications of aging with HIV infection: perspectives and the future medical care agenda [J]. AIDS, 2017, 31 Suppl 2:S129-129S135. DOI: 10.1097/ QAD.0000000000001478.

备注/Memo

备注/Memo:
[ 基金项目] “十二五”国家科技重大专项(2012ZX10001003); “十三五”国家科技重大专项(2017ZX10202101)
[ 通信作者] 李太生,Email: litsh@263.net; 王福生,Email: fswang302@163.com;高福,Email: gaof@im.ac.cn
更新日期/Last Update: 2018-12-30